BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Won HS, Kim YA, Lee JS, Jeon EK, An HJ, Sun DS, Ko YH, Kim JS. Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer. Cancer Invest 2013;31:516-21. [PMID: 23902164 DOI: 10.3109/07357907.2013.826239] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Engin A. Obesity-associated Breast Cancer: Analysis of risk factors. Adv Exp Med Biol 2017;960:571-606. [PMID: 28585217 DOI: 10.1007/978-3-319-48382-5_25] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
2 Rego SL, Helms RS, Dréau D. Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer. Immunol Res 2014;58:87-100. [PMID: 24072428 DOI: 10.1007/s12026-013-8434-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
3 Manjili SH, Isbell M, Ghochaghi N, Perkinson T, Manjili MH. Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse. Semin Cancer Biol 2021:S1044-579X(21)00073-0. [PMID: 33785450 DOI: 10.1016/j.semcancer.2021.03.023] [Reference Citation Analysis]
4 Lin S, Gan Z, Han K, Yao Y, Min D. Interleukin-6 as a Prognostic Marker for Breast Cancer: A Meta-analysis. Tumori 2015;101:535-41. [DOI: 10.5301/tj.5000357] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
5 Omokehinde T, Johnson RW. GP130 Cytokines in Breast Cancer and Bone. Cancers (Basel) 2020;12:E326. [PMID: 32023849 DOI: 10.3390/cancers12020326] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
6 Milovanović J, Todorović-raković N, Radulovic M. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer. Cytokine 2019;118:93-8. [DOI: 10.1016/j.cyto.2018.02.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
7 Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine. Int J Mol Sci. 2017;18. [PMID: 28841158 DOI: 10.3390/ijms18091852] [Cited by in Crossref: 378] [Cited by in F6Publishing: 369] [Article Influence: 94.5] [Reference Citation Analysis]
8 Eiró N, Sendon-Lago J, Seoane S, Bermúdez MA, Lamelas ML, Garcia-Caballero T, Schneider J, Perez-Fernandez R, Vizoso FJ. Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells. Oncotarget 2014;5:10692-708. [PMID: 25296979 DOI: 10.18632/oncotarget.2530] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
9 Casneuf T, Axel AE, King P, Alvarez JD, Werbeck JL, Verhulst T, Verstraeten K, Hall BM, Sasser AK. Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer. Breast Cancer (Dove Med Press) 2016;8:13-27. [PMID: 26893580 DOI: 10.2147/BCTT.S92414] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
10 Vaysse C, Lømo J, Garred Ø, Fjeldheim F, Lofteroed T, Schlichting E, McTiernan A, Frydenberg H, Husøy A, Lundgren S, Fagerland MW, Richardsen E, Wist EA, Muller C, Thune I. Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. NPJ Breast Cancer 2017;3:19. [PMID: 28649659 DOI: 10.1038/s41523-017-0015-9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
11 Bernasochi GB, Bell JR, Simpson ER, Delbridge LM, Boon WC. Impact of Estrogens on the Regulation of White, Beige, and Brown Adipose Tissue Depots. In: Terjung R, editor. Comprehensive Physiology. Wiley; 2011. pp. 457-75. [DOI: 10.1002/cphy.c180009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Choudhary MM, France TJ, Teknos TN, Kumar P. Interleukin-6 role in head and neck squamous cell carcinoma progression. World J Otorhinolaryngol Head Neck Surg 2016;2:90-7. [PMID: 29204553 DOI: 10.1016/j.wjorl.2016.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
13 Heo TH, Wahler J, Suh N. Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancer. Oncotarget 2016;7:15460-73. [PMID: 26840088 DOI: 10.18632/oncotarget.7102] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 15.8] [Reference Citation Analysis]
14 Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11-20. [PMID: 24986424 DOI: 10.1016/j.cyto.2014.05.024] [Cited by in Crossref: 291] [Cited by in F6Publishing: 276] [Article Influence: 41.6] [Reference Citation Analysis]
15 Curtis KJ, Mai C, Martin H, Oberman AG, Alderfer L, Romero-Moreno R, Walsh M, Mitros SF, Thomas SG, Dynako JA, Zimmer DI, McNamara LM, Littlepage LE, Niebur GL. The effect of marrow secretome and culture environment on the rate of metastatic breast cancer cell migration in two and three dimensions. Mol Biol Cell 2021;32:1009-19. [PMID: 33689396 DOI: 10.1091/mbc.E19-12-0682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Courtier N, Gambling T, Barrett-Lee P, Oliver T, Mason MD. The volume of liver irradiated during modern free-breathing breast radiotherapy: Implications for theory and practice. Radiography (Lond) 2019;25:103-7. [PMID: 30955681 DOI: 10.1016/j.radi.2018.12.003] [Reference Citation Analysis]
17 Tvedt TH, Lie SA, Reikvam H, Rye KP, Lindås R, Gedde-Dahl T, Ahmed AB, Bruserud Ø. Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation. Int J Mol Sci 2016;17:E1823. [PMID: 27809289 DOI: 10.3390/ijms17111823] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]